Tag: Vaccines
“Indian vaccine industry has a promising future”
Dr Krishna Ella, Executive Chairman, Bharat Biotech and President, IVMA shares his insights on the industry’s journey so far and the future potential.
ICDRA Conference: Regulators, policymakers & health officials from over 200 countries...
India licensed eighth vaccines for use during the pandemic through a proper regulatory process, said the Union MoS for Health and Family Welfare, Anupriya Singh Patel
IQVIA conducts over 45 vaccine studies in India during last 5...
The company’s success in vaccine trials is driven by its extensive site network, comprising over 130 locations across India
Dr V K Paul emphasizes prioritizing creation of a strong primary...
Dr V K Paul, Member (Health), NITI Aayog inaugurates National Conference on “Universal Access to Healthcare: Digital Solutions” in New Delhi
National Biopharma Mission: Bioeconomy to spearhead India’s future growth story, says...
National Biopharma Mission (NBM) achieved a milestone by launching 18 successful products and 200 grantees in Vaccines, Biotherapeutics & Medical Devices and Diagnostics
Merck KGaA announces €300 million investment in South Korea for new...
The new €300 million Bioprocessing Production Center in Daejeon will manufacture vaccines, cell and gene therapies, and protein-based therapies, creating 300 new jobs
Parexel named best CRO at 17th Annual Vaccine Industry Excellence Awards
Over the last five years Parexel has conducted more than 225 clinical projects in the infectious disease and vaccine therapeutic area involving more than 9,150 global sites
BSV collaborates with FOGSI for raising importance of spreading health tips...
Aims to promote awareness on breastfeeding and post-partum care
Depart of Health & Family Welfare wins award in highest single...
The tender was finalized in July 2022 in an efficient and transparent manner and orders placed under for value of approximately 1544 crores
Merck Study: mRNA technology a ‘Game Changer’ for Asia-Pacific vaccine manufacturers
More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand